Safety, Tolerability, Pharmacokinetics & Antitumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Have Progressed on Prior Therapy With an Epidermal Growth Factor ReceptorTyrosine Kinase Inhibator Agent

Trial Profile

Safety, Tolerability, Pharmacokinetics & Antitumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Have Progressed on Prior Therapy With an Epidermal Growth Factor ReceptorTyrosine Kinase Inhibator Agent

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus First in man; Registrational; Therapeutic Use
  • Acronyms AURA; AURA extension; AURAext
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Sep 2017 Results (data cut off: 1 Nov, 2016; n = 411) of a pooled analysis from AURA extension AURA2 studies assessing overall survival in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with osimertinib, presented at the 42nd European Society for Medical Oncology Congress.
    • 01 Aug 2017 Results of EGFR mutation analysis data from two studies (AURA2 and AURA extension) published in the Journal of Thoracic Oncology
    • 24 Jul 2017 Results of the paired tumor biopsy cohorts evaluating modulation of biomarker expression were published in the Journal of Thoracic Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top